Partial
Needs Correction
Patient Risk:
Medium
Summary
Two indication claims are partially supported but omit key label constraints (age scope for treatment; additional replacement eligibility criteria beyond virologic suppression). The FDA approval date is not verifiable from the provided label sections.
Category Scores
Accurate Statements
Dovato is indicated to replace the current antiretroviral regimen in adult patients who are virologically suppressed on a stable background regimen.
Supported in part by Indications and Usage, which includes replacement for virologically suppressed patients on a stable antiretroviral regimen with additional requirements not included in the claim.
Unsupported Statements
Dovato received FDA approval on March 4, 2020.
Not supported by the provided label sections (Indications and Usage, Clinical Pharmacology, Clinical Studies) because no approval date appears there.
Contradictions
Important Omissions
Treatment indication is not limited to adults; the label includes adolescents 12 years of age and older and weighing at least 25 kg.
Importance:
Moderate
Replacement indication includes additional eligibility criteria beyond virologic suppression on a stable regimen: no history of treatment failure and no known substitutions associated with resistance to the individual components of DOVATO.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Omitted indication scope and eligibility criteria could lead to overbroad use relative to the label’s stated replacement and population constraints.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Needs Correction
Primary Issue
Indication statements are incomplete relative to the label (missing adolescent/weight scope and additional replacement eligibility criteria). Approval date is not supported by the provided label sections.
Suggested Improvement
Update the treatment indication to include adolescents 12+ years (≥25 kg) per Indications and Usage, and expand the replacement criteria to include no history of treatment failure and no known resistance-associated substitutions to DOVATO components; remove or separately source the approval date since it is not present in the provided label excerpts.